FLGT · Fulgent Genetics, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $330M – $340M | $323.93M | $322.67MG | $283.47M | $289.21MG | $618.97MG | $992.58MG | $421.71M | $32.53M | $21.35M | $18.73M | $18.28M | $9.58M | $1.28M | |
| — | — | — | — | $200K | $300K | $420K | $145K | $0 | — | — | — | — | — | |
| — | $208.67M | $191.8M | $176.26M | $184.76M | $252.07M | $215.53M | $89.81M | $14.11M | $10.7M | $8.55M | $6.72M | $5.07M | $936K | |
| — | $115.26M | $130.88M | $107.22M | $104.46M | $366.9M | $777.05M | $331.91M | $18.42M | $10.65M | $10.18M | $11.55M | $4.51M | $342K | |
| — | — | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% | 78.7% | 56.63% | 49.9% | 54.35% | 63.22% | 47.07% | 26.76% | |
| — | $56.76M | $53.91M | $48.82M | $41.44M | $28.91M | $24.22M | $11.58M | $6.54M | $5.53M | $4.22M | $3.56M | $4.43M | $521K | |
| — | $50.07M | $43.37M | $36.25M | $41.47M | $38.92M | $24.44M | $14.95M | $5.9M | $4.65M | $4.21M | $2.47M | $2.67M | $581K | |
| — | $119.86M | $116.66M | $88.11M | $89M | $111.07M | $50.73M | $15.22M | $6.41M | $5.54M | $5.23M | $4.61M | $2.42M | $230K | |
| — | $8.69M | $8.03M | $7.97M | $7.85M | $6.5M | $1.71M | — | — | — | — | — | — | — | |
| — | $25.83M | $24.12M | $24.93M | $26.14M | $32.66M | $11M | $2.96M | $2.11M | — | $1.73M | $1.17M | $575K | $196K | |
| — | $237.55M | $221.97M | $181.13M | $299.99M | $188.37M | $101.1M | $41.75M | $18.85M | $15.72M | $13.66M | $10.64M | $9.52M | $1.33M | |
| — | -$122.28M | -$91.1M | -$73.92M | -$195.53M | $178.53M | $675.95M | $290.16M | -$428K | -$5.07M | -$3.48M | $918K | -$5.01M | -$990K | |
| — | — | -28.23% | -26.08% | -67.61% | 28.84% | 68.1% | 68.8% | -1.32% | -23.75% | -18.59% | 5.02% | -52.34% | -77.46% | |
| — | -$96.46M | -$66.97M | -$48.99M | -$169.39M | $211.19M | $686.96M | $293.12M | $1.68M | — | -$1.75M | $2.09M | -$4.44M | -$794K | |
| — | $120K | $75K | -$170K | $488K | $346K | $117K | $20K | — | — | — | — | — | — | |
| — | $29.87M | $30.92M | $31.3M | $21.61M | $5.62M | — | — | — | — | — | — | — | — | |
| — | $29.83M | $21.07M | $21.96M | $21.44M | $5.5M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$488K | -$777K | -$935K | -$524K | $0 | — | — | |
| — | -$92.45M | -$70.03M | -$51.96M | -$174.09M | $184.03M | $677.3M | $291.68M | $409K | -$4.64M | -$3M | -$4.47M | -$4.99M | -$990K | |
| — | -$6.98M | -$8.39M | -$8.14M | $1.15M | $42.1M | $174.8M | $72.53M | $43K | $36K | -$1.02M | $920K | $0 | $0 | |
| — | -$84.01M | -$60.51M | -$42.71M | -$167.83M | $143.4M | $507.36M | $214.31M | -$411K | -$5.61M | -$2.51M | -$5.35M | -$8.31M | -$4.28M | |
| — | — | -18.75% | -15.07% | -58.03% | 23.17% | 51.12% | 50.82% | -1.26% | -26.26% | -13.4% | -29.26% | -86.82% | -335.13% | |
| — | -$1.09M | -$1.12M | -$1.11M | -$7.41M | -$1.48M | -$1.13M | — | — | — | — | — | — | — | |
| — | -$84.38M | -$60.51M | -$42.71M | -$167.83M | $143.4M | $507.36M | — | — | — | -$2.51M | -$13.67M | — | — | |
| — | -$88.46M | -$52.63M | -$44.28M | -$145.72M | $123.26M | $506.17M | $214.6M | -$230K | -$5.6M | -$2.45M | -$5.45M | -$8.31M | -$4.28M | |
| shares | — | — | 30.78M | 30.24M | 29.78M | 30.1M | 29.41M | 22.69M | 18.71M | 17.98M | 17.74M | 13.71M | 11.84M | 0 |
| shares | — | — | 30.78M | 30.24M | 29.78M | 30.96M | 30.98M | 24.06M | 18.71M | 17.98M | 17.74M | 13.71M | 11.84M | 0 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $110.59M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2026-06-30 | USD 482,000 | 10-Q filed 2026-07-30 |
| Finance lease liabilities | 2026-06-30 | USD 181,000 | 10-Q filed 2026-07-30 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent notes payable | 2026-06-30 | USD 1,476,000 | 10-Q filed 2026-07-30 |
| Operating lease liabilities | 2026-06-30 | USD 7,464,000 | 10-Q filed 2026-07-30 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 18 similar-size Diagnostics & Research companies (of 50 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Laboratory Services | $322,224,000 | $283,470,000 | $289,213,000 | $618,968,000 | $992,584,000 |
| Therapeutic Development | $447,000 | $0 | $0 | $0 | $0 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $296,552,000 | $259,132,000 | $268,977,000 | $603,148,000 | $978,978,000 | $415,334,000 | $25,014,000 |
| Non Us | $26,119,000 | $24,338,000 | $20,236,000 | $15,820,000 | $13,606,000 | $6,378,000 | $7,514,000 |
| Other Countries | $13,213,000 | $11,700,000 | $8,790,000 | $6,881,000 | — | — | — |
| China | $12,906,000 | $12,638,000 | $11,446,000 | $8,939,000 | — | — | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Laboratory Services | -$7,212,000 | -$4,912,000 | -$16,857,000 | $179,343,000 | $675,953,000 |
| Therapeutic Development | -$19,847,000 | -$16,560,000 | -$7,671,000 | -$816,000 | $0 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Laboratory Services | -2.2% | -1.7% | -5.8% | 29% | 68.1% |
| Therapeutic Development | -4440% | — | — | — | — |